摘要
目的探讨恩替卡韦在肺结核合并慢性乙型肝炎患者治疗中的临床效果。方法随机选取该院2015年5月—2017年5月收治的肺结核合并慢性乙型肝炎患者30例,依据治疗方法将这些患者分为常规治疗组(n=15)和常规治疗联合恩替卡韦治疗组(恩替卡韦组,n=15)两组,对两组患者的肝功能及肝纤维化指标、HBV DNA阴转、病灶吸收、痰菌转阴情况、不良反应发生情况进行统计分析。结果常规治疗组患者治疗后的ALT、AST、GGT、ALP、TBIL水平(223.3±26.5)U/L、(180.2±9.2)U/L、(175.6±9.4)U/L、(289.2±23.6)U/L、(89.2±17.2)μmol/L均显著高于恩替卡韦组(55.2±15.3)U/L、(41.3±8.5)U/L、(98.6±8.1)U/L、(172.3±25.4)U/L、(27.5±25.3)μmol/L(P<0.05),ALB水平(43.5±4.0)g/L显著高于常规治疗组(38.5±3.2)g/L(P<0.05),HA、LN、IV-C、PⅢNP水平(111.2±21.2)ng/m L、(168.8±18.2)ng/m L、(121.2±14.0)ng/m L、(18.0±1.7)ng/m L均显著高于恩替卡韦组(73.1±10.7)ng/m L、(105.2±10.6)ng/m L、(69.2±6.3)ng/m L、(12.3±1.1)ng/m L(P<0.05),常规性治疗组HBV DNA阴转率、病灶吸收率、痰菌转阴率6.7%(1/15)、46.7%(7/15)、53.3%(8/15)均显著低于恩替卡韦组66.7%(10/15)、93.3%(14/15)、86.7%(13/15)(P<0.05),不良反应发生率40.0%(6/15)显著低于常规治疗组66.7%(10/15)(P<0.05)。结论恩替卡韦在肺结核合并慢性乙型肝炎患者治疗中的临床效果显著。
Objective To discuss the clinical effect of entecavir in treatment of patients with pulmonary tuberculosis and chronic hepatitis B. Methods 30 cases of patients with pulmonary tuberculosis and chronic hepatitis B admitted and treated in our hospital from May 2015 to May 2017 were selected and divided into two groups with 15 cases in each according to the treatment method, the patients were divided into the routine treatment group and routine treatment and entecavir treatment group(entecavir treatment group), and the liver function and hepatic fibrosis indexes, HBV DNA negative conversion rate, focus absorption, sputum bacteria negative conversion condition and occurrence of adverse reactions were statistically analyzed. Results The ALT,AST,GGT,ALP,TBIL levels in the routine treatment group after treatment were obviously higher than those in the entecavir group, [(223.3±26.5)U/L,(180.2±9.2)U/L,(175.6±9.4)U/L,(289.2±23.6)U/L,(89.2±17.2)μmol/L vs(55.2±15.3)U/L,(41.3±8.5)U/L,(98.6±8.1)U/L,(172.3±25.4)U/L,(27.5±25.3)μmol/L](P<0.05), and the ALB level was obviously higher than that in the routine treatment group, [(43.5±4.0)g/L vs(38.5±3.2)g/L](P<0.05), and the HA,LN,IV-C,P Ⅲ NP levels in the routine treatment group were obviously higher than those in the entecavir group[(111.2±21.2),(168.8±18.2),(131.2±14.0),(18.0±1.7)ng/m L vs(73.1±10.7),(105.2±10.6),(69.2±6.3),(12.3±1.1)ng/m L](P<0.05), and HBV DNA negative conversion rate, focus absorption rate and sputum bacteria negative conversion rate in the routine treatment group were obviously lower than those in the entecavir group, [6.7%(1/15),46.7%(7/15),53.3%(8/15) vs 66.7%(10/15),93.3%(14/15),86.7%(13/15)](P<0.05), and the incidence rate of adverse reactions was obviously lower than those in the routine treatment group,[40.0%(6/15) vs 66.7%(10/15)](P <0.05). Conclusion The clinical effect of entecavir in treatment of patients with pulmonary tuberculosis and chronic hepatitis B is obvious.
出处
《中外医疗》
2017年第24期137-139,共3页
China & Foreign Medical Treatment
关键词
恩替卡韦
肺结核合并慢性乙型肝炎
临床效果
Entecavir
Pulmonary tuberculosis and chronic hepatitis B
Clinical effect
